OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kasi on the Application of Pharmacogenomics in CRC

February 5th 2019

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the application of pharmacogenomics in colorectal cancer (CRC).

Dr. Hilal on the Benefit of Maintenance Rituximab in Patients With MCL

February 5th 2019

Talal Hilal, MB, BCh, assistant professor of Medicine at Mayo Clinic, discusses the benefit of maintenance rituximab (Rituxan) in the treatment of patients with mantle cell lymphoma (MCL).

Dr. Chari on Role of Immunotherapy in Myeloma

February 5th 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses the role of immunotherapy in the treatment of patients with myeloma.

Dr. Burris Discusses Promise of T-DM1 in HER2+ Breast Cancer

February 5th 2019

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the promise of T-DM1 in the treatment of patients with HER2-positive breast cancer.

Dr. Grisham on Frontline Treatment for Low-Grade Serous Ovarian Cancer

February 5th 2019

Rachel N. Grisham, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses frontline treatment options for patients with low-grade serous ovarian cancer.

Dr. Hamilton on Adjuvant Therapy for HER2+ Breast Cancer

February 2nd 2019

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses adjuvant therapy for the treatment of patients with HER2-positive breast cancer.

Dr. Maziarz Discusses Promise of Tisagenlecleucel in DLBCL

February 2nd 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses the promise of tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.

Identifying Factors That Limit Access to Prostate Cancer Therapy

February 2nd 2019

Jay H. Fowke, PhD, MPH, MS, chief, Division of Epidemiology, professor of preventive medicine, University of Tennessee Health Science Center, discusses factors that can lead to disparity in access to prostate cancer therapy.

Dr. Padda on Overcoming Resistance to Osimertinib in EGFR+ NSCLC

February 1st 2019

Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, member, Stanford Cancer Institute, discusses therapy beyond osimertinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

Dr. Parekh on Potential Biomarker for Novel Drug in Myeloma

February 1st 2019

Samir Parekh, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses a promising potential biomarker for response to selinexor in patients with myeloma.

Dr. Eskander on Combination Approaches With Immunotherapy in Ovarian Cancer

February 1st 2019

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses combination approaches with immunotherapy in ovarian cancer.

Dr. Katzel on Differences in Therapy Between Men and Women With Head and Neck Cancer

February 1st 2019

Jed A. Katzel, MD, Hematology, Kaiser Permanente Santa Clara Medical Center, discusses differences in treatment decisions between men and women with head and neck cancer.

Dr. Graff on Tamoxifen De-Escalation in Breast Cancer

February 1st 2019

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health, and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the use of tamoxifen in the treatment of patients with breast cancer.

Dr. Dorff on the Status of Immunotherapy in Prostate Cancer

February 1st 2019

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the status of immunotherapy in prostate cancer.

Dr. Chao on Practice-Changing Data in Metastatic Gastroesophageal Cancer

January 31st 2019

Joseph Chao, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses practice-changing data in metastatic gastroesophageal (GEJ) cancer.

Dr. Fakih on Durvalumab and Tremelimumab in CRC

January 31st 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the combination of durvalumab (Imfinzi) and tremelimumab in patients with metastatic colorectal cancer (mCRC).

Dr. Chung on Sequencing Chemotherapy Regimens in Metastatic Pancreatic Cancer

January 31st 2019

Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, Director Phase I Program, City of Hope, discusses sequencing chemotherapy regimens in patients with metastatic pancreatic cancer.

Dr. Verstovsek on Benefit of Ruxolitinib in Polycythemia Vera

January 31st 2019

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the benefit of ruxolitinib in polycythemia vera.

Dr. Burgess on Understanding Molecular Subtypes of Prostate Cancer

January 31st 2019

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses the importance of understanding the molecular subtypes of prostate cancer.

Dr. Cristofanilli on Using CTC to Stratify Patients With Breast Cancer

January 31st 2019

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses using circulating tumor cells to risk stratify patients with advanced breast cancer.